These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 8137328)

  • 1. Prevention of carcinogenesis by protease inhibitors.
    Kennedy AR
    Cancer Res; 1994 Apr; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer prevention by protease inhibitors.
    Kennedy AR
    Prev Med; 1993 Sep; 22(5):796-811. PubMed ID: 8234219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mechanisms of antitumorigenesis by protease inhibitors.
    Kennedy AR
    Basic Life Sci; 1993; 61():301-7. PubMed ID: 8304942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bowman-Birk soybean protease inhibitor as an anticarcinogen.
    Yavelow J; Finlay TH; Kennedy AR; Troll W
    Cancer Res; 1983 May; 43(5 Suppl):2454s-2459s. PubMed ID: 6682011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent.
    Kennedy AR
    Am J Clin Nutr; 1998 Dec; 68(6 Suppl):1406S-1412S. PubMed ID: 9848508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of oral carcinogenesis by a protease inhibitor.
    Messadi DV; Billings P; Shklar G; Kennedy AR
    J Natl Cancer Inst; 1986 Mar; 76(3):447-52. PubMed ID: 3081747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the protease inhibitor antipain on cell malignant transformation.
    Vaccari M; Argnani A; Horn W; Silingardi P; Giungi M; Mascolo MG; Bartoli S; Grilli S; Colacci A
    Anticancer Res; 1999; 19(1A):589-96. PubMed ID: 10226603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors.
    Billings PC; Carew JA; Keller-McGandy CE; Goldberg AL; Kennedy AR
    Proc Natl Acad Sci U S A; 1987 Jul; 84(14):4801-5. PubMed ID: 3299374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
    Kennedy AR; Szuhaj BF; Newberne PM; Billings PC
    Nutr Cancer; 1993; 19(3):281-302. PubMed ID: 8346077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor.
    St Clair WH; Billings PC; Carew JA; Keller-McGandy C; Newberne P; Kennedy AR
    Cancer Res; 1990 Feb; 50(3):580-6. PubMed ID: 2297699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Workshop report from the Division of Cancer Etiology, National Cancer Institute, National Institutes of Health. Protease inhibitors as cancer chemopreventive agents.
    Cancer Res; 1989 Jan; 49(2):499-502. PubMed ID: 2910469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of protease inhibitors on radiation transformation in vitro.
    Kennedy AR; Little JB
    Cancer Res; 1981 Jun; 41(6):2103-8. PubMed ID: 7237415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor.
    Kennedy AR; Beazer-Barclay Y; Kinzler KW; Newberne PM
    Cancer Res; 1996 Feb; 56(4):679-82. PubMed ID: 8630994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor.
    Wan XS; Meyskens FL; Armstrong WB; Taylor TH; Kennedy AR
    Cancer Epidemiol Biomarkers Prev; 1999 Jul; 8(7):601-8. PubMed ID: 10428197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues.
    Kennedy AR; Manzone H
    J Cell Biochem Suppl; 1995; 22():188-94. PubMed ID: 8538198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA.
    Kennedy AR; Billings PC; Maki PA; Newberne P
    Nutr Cancer; 1993; 19(2):191-200. PubMed ID: 8502589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors.
    Yavelow J; Caggana M; Beck KA
    Cancer Res; 1987 Mar; 47(6):1598-601. PubMed ID: 3545448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation.
    Chen H; Liu J; Zhao CQ; Diwan BA; Merrick BA; Waalkes MP
    Toxicol Appl Pharmacol; 2001 Sep; 175(3):260-8. PubMed ID: 11559025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.